Core Insights - TG Therapeutics reported a significant increase in revenue and achieved profitability, but the stock price fell sharply due to investor disappointment [1][4][7] Revenue Performance - The company's revenue for the first quarter was nearly $121 million, almost double the $63.5 million from the same period in 2024, driven primarily by Briumvi sales [2][6] - Analysts had a collective revenue estimate of $117 million, indicating that the actual revenue exceeded expectations [4] Profitability - TG Therapeutics posted a net profit of just over $5 million, or $0.03 per share, compared to an almost $11 million loss in the first quarter of 2024 [4] - The consensus estimate for earnings per share was $0.16, suggesting that the actual profit fell short of analyst expectations [4][7] Pipeline Developments - The company is conducting two phase 1 trials for Briumvi: one for subcutaneous use in relapsing MS patients and another for myasthenia gravis [5] - Additionally, TG is developing a CAR T cell therapy, azercabtagene zapreleucel, which is currently in enrollment for a phase 1 trial [5] Guidance Update - TG Therapeutics raised its guidance for domestic Briumvi sales in 2025 to $560 million, up from a previous estimate of $525 million [6] - Overall revenue guidance was also increased to $575 million from $540 million [6]